Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement

被引:25
作者
Knipp, Sabine
Gattermann, Norbert
Schapira, Marc
Kaeferstein, Herbert
Germing, Ulrich
机构
[1] CHU Vaudois, Dept Haematol, CH-1011 Lausanne, Switzerland
[2] Univ Dusseldorf, Dept Haematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany
[3] Univ Cologne, Inst Legal Med, D-50823 Cologne, Germany
关键词
arsenic; arsenic trioxide; cerebrospinal fluid; blood-cerebrospinal fluid-barrier; acute promyelocytic leukemia;
D O I
10.1016/j.leukres.2007.03.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL) included meningeal infiltration. Since he had previously experienced ATRA syndrome, he received arsenic trioxide (ATO) plus intrathecal therapy with cytarabine, prednisone, and methotrexate. We measured the concentration of arsenic in his cerebrospinal fluid (CSF). Arsenic showed a peak CSF concentration of 0.008 mg/l (0.11 mu mol/l) and a nadir of 0.002 mg/l (0.027 mu mol/l), both representing about 14% of blood levels. ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1585 / 1587
页数:3
相关论文
共 11 条
[1]  
Chen GQ, 1997, BLOOD, V89, P3345
[2]  
Chen GQ, 1996, BLOOD, V88, P1052
[3]  
FRIEDHEIM E, 1983, LANCET, V1, P981
[4]   Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients [J].
Niu, C ;
Yan, H ;
Yu, T ;
Sun, HP ;
Liu, JX ;
Li, XS ;
Wu, W ;
Zhang, FQ ;
Chen, Y ;
Zhou, L ;
Li, JM ;
Zeng, XY ;
Yang, RRO ;
Yuan, MM ;
Ren, MY ;
Gu, FY ;
Cao, Q ;
Gu, BW ;
Su, XY ;
Chen, GQ ;
Xiong, SM ;
Zhang, TD ;
Waxman, S ;
Wang, ZY ;
Chen, Z ;
Hu, J ;
Shen, ZX ;
Chen, SJ .
BLOOD, 1999, 94 (10) :3315-3324
[5]   Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells [J].
Shao, WL ;
Fanelli, M ;
Ferrara, FF ;
Riccioni, R ;
Rosenauer, A ;
Davison, K ;
Lamph, WW ;
Waxman, S ;
Pelicci, PG ;
Lo Coco, F ;
Avvisati, G ;
Testa, U ;
Peschle, C ;
Gambacorti-Passerini, C ;
Nervi, C ;
Miller, WH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (02) :124-133
[6]   Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APE) .2. Clinical efficacy and pharmacokinetics in relapsed patients [J].
Shen, ZX ;
Chen, GQ ;
Ni, JH ;
Li, XS ;
Xiong, SM ;
Qiu, QY ;
Zhu, J ;
Tang, W ;
Sun, GL ;
Yang, KQ ;
Chen, Y ;
Zhou, L ;
Fang, ZW ;
Wang, YT ;
Ma, J ;
Zhang, P ;
Zhang, TD ;
Chen, SJ ;
Chen, Z ;
Wang, ZY .
BLOOD, 1997, 89 (09) :3354-3360
[7]   United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia [J].
Soignet, SL ;
Frankel, SR ;
Douer, D ;
Tallman, MS ;
Kantarjian, H ;
Calleja, E ;
Stone, RM ;
Kalaycio, M ;
Scheinberg, DA ;
Steinherz, P ;
Sievers, EL ;
Coutré, S ;
Dahlberg, S ;
Ellison, R ;
Warrell, RP .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3852-3860
[8]   Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide [J].
Soignet, SL ;
Maslak, P ;
Wang, ZG ;
Jhanwar, S ;
Calleja, E ;
Dardashti, LJ ;
Corso, D ;
DeBlasio, A ;
Gabrilove, J ;
Scheinberg, DA ;
Pandolfi, PP ;
Warrell, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (19) :1341-1348
[9]  
Zheng W, 2001, MICROSC RES TECHNIQ, V52, P89, DOI 10.1002/1097-0029(20010101)52:1<89::AID-JEMT11>3.3.CO
[10]  
2-U